Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects

Molecular Pharmaceutics

Volumn 12, Issue 7, 2015, Pages 2544-2550

  Liu, Yuan ^a   Goswami, Rajib K ^a   Liu, Cheng ^a   Sinha, Subhash C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

38C2; aldolase; alpha(v)beta(3); antibody; bispecific; chemical; integrin; legumain; protease

Indexed keywords

38C 2 3; 38C 2 4; 38C 2 5; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; LEGUMAIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTIBODY ALDOLASE; CYSTEINE PROTEINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN TARGETING; THERAPY EFFECT; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEASES; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRIN ALPHAVBETA3; MICE;

EID: 84936804307     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00257     Document Type: Article

References (38)

1. Chen, J. M.; Dando, P. M.; Rawlings, N. D.; Brown, M. A.; Young, N. E.; Stevens, R. A.; Hewitt, E.; Watts, C.; Barrett, A. J. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase J. Biol. Chem. 1997, 272, 8090-98
2. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 2010, 10, 9-22
3. Haugen, M. H.; Johansen, H. T.; Pettersen, S. J.; Solberg, R.; Brix, K.; Flatmark, K.; Maelandsmo, G. M. Nuclear legumain activity in colorectal cancer PLoS One 2013, 8, e52980
4. Shirahama-Noda, K.; Yamamoto, A.; Sugihara, K.; Hashimoto, N.; Asano, M.; Nishimura, M.; Hara-Nishimura, I. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice J. Biol. Chem. 2003, 278, 33194-9
5. Chen, J. M.; Fortunato, M.; Stevens, R. A.; Barrett, A. J. Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase Biol. Chem. 2001, 382, 777-83
6. Brix, K.; McInnes, J.; Al-Hashimi, A.; Rehders, M.; Tamhane, T.; Haugen, M. H. Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges Protoplasma 2015, 252 (3) 755-74
7. Morita, Y.; Araki, H.; Sugimoto, T.; Takeuchi, K.; Yamane, T.; Maeda, T.; Yamamoto, Y.; Nishi, K.; Asano, M.; Shirahama-Noda, K.; Nishimura, M.; Uzu, T.; Hara-Nishimura, I.; Koya, D.; Kashiwagi, A.; Ohkubo, I. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells FEBS Lett. 2007, 581, 1417-24
8. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines Cell 2002, 110, 673-87
9. Luo, Y.; Zhou, H.; Krueger, J.; Kaplan, C.; Lee, S. H.; Dolman, C.; Markowitz, D.; Wu, W.; Liu, C.; Reisfeld, R. A.; Xiang, R. Targeting tumor-associated macrophages as a novel strategy against breast cancer J. Clin. Invest. 2006, 116, 2132-41
10. Popkov, M.; Rader, C.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., III. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector Int. J. Cancer 2006, 119, 1194-207
11. Liu, C.; Sun, C.; Huang, H.; Janda, K.; Edgington, T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy Cancer Res. 2003, 63, 2957-64
12. Guo, F.; Das, S.; Mueller, B. M.; Barbas, C. F., III; Lerner, R. A.; Sinha, S. C. Breaking the one antibody-one target axiom Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11009-14
13. Liu, Y.; Bajjuri, K. M.; Liu, C.; Sinha, S. C. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug Mol. Pharmaceutics 2012, 9, 168-75
14. Dall, E.; Brandstetter, H. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 10940-5
15. Dall, E.; Brandstetter, H. Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2012, 68, 24-31
16. Gavrilyuk, J. I.; Wuellner, U.; Salahuddin, S.; Goswami, R. K.; Sinha, S. C.; Barbas, C. F., III. An efficient chemical approach to bispecific antibodies and antibodies of high valency Bioorg. Med. Chem. Lett. 2009, 19, 3716-20
17. Doppalapudi, V. R.; Huang, J.; Liu, D.; Jin, P.; Liu, B.; Li, L.; Desharnais, J.; Hagen, C.; Levin, N. J.; Shields, M. J.; Parish, M.; Murphy, R. E.; Del Rosario, J.; Oates, B. D.; Lai, J.-Y.; Matin, M. J.; Ainekulu, Z.; Bhat, A.; Bradshaw, C. W.; Woodnutt, G.; Lerner, R. A.; Lappe, R. W. Chemical generation of bispecific antibodies Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 22611-6
18. Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F., III. A chemically programmed monoclonal antibody for cancer therapy Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5396-400
19. Sinha, S. C.; Das, S.; Li, L.-S.; Lerner, R. A.; Barbas, C. F., III. Preparation of integrin alpha(v)beta(3)-targeting Ab 38C2 constructs Nat. Protoc. 2007, 2, 449-56
20. Li, L.-S.; Rader, C.; Matsushita, M.; Das, S.; Barbas, C. F., III; Lerner, R. A.; Sinha, S. C. Chemical-Adaptor Immunotherapy: Design, synthesis and evaluation of novel integrin-targeting devices J. Med. Chem. 2004, 47, 5630-40
21. Goswami, R. K.; Bajjuri, K. M.; Forsyth, J. S.; Das, S.; Hassenpflug, W.; Huang, Z. Z.; Lerner, R. A.; Felding-Habermann, B.; Sinha, S. C. Chemically Programmed Antibodies Targeting Multiple Alpha(V) Integrins And Their Effects On Tumor-Related Functions In Vitro Bioconjugate Chem. 2011, 22, 1535-44
22. Rader, C. Chemically programmed antibodies Trends Biotechnol. 2014, 32, 186-97
23. McEnaney, P. J.; Parker, C. G.; Zhang, A. X.; Spiegel, D. A. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease ACS Chem. Biol. 2012, 7, 1139-51
24. Gavrilyuk, J. I.; Wuellner, U.; Barbas, C. F., III. β-Lactam-based approach for the chemical programming of aldolase antibody 38C2 Bioorg. Med. Chem. Lett. 2009, 19, 1421-4
25. Götz, M. G.; James, K. E.; Hansell, E.; Dvorák, J.; Seshaadri, A.; Sojka, D.; Kopacek, P.; McKerrow, J. H.; Caffrey, C. R.; Powers, J. C. Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens J. Med. Chem. 2008, 51, 2816-32
26. Duggan, M. E.; Duong, L. T.; Fisher, J. E.; Hamill, T. G.; Hoffman, W. F.; Huff, J. R.; Ihle, N. C.; Leu, C. T.; Nagy, R. M.; Perkins, J. J.; Rodan, S. B.; Wesolowski, G.; Whitman, D. B.; Zartman, A. E.; Rodan, G. A.; Hartman, G. D. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist J. Med. Chem. 2000, 43, 3736-45
27. Wagner, J.; Lerner, R. A.; Barbas, C. F., III. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes Science 1995, 270, 1797-800
28. Goswami, R. K.; Huang, Z.-Z.; Forsyth, J. S.; Felding-Habermann, B.; Sinha, S. C. Multiple Catalytic Aldolase Antibodies Suitable For Chemical Programming Bioorg. Med. Chem. Lett. 2009, 19, 3821-4
29. List, B.; Barbas, C. F., III; Lerner, R. A. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15351-5
30. Friedlander, D. R.; Zagzag, D.; Shiff, B.; Cohen, H.; Allen, J. C.; Kelly, P. J.; Grume, M. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves av and β1 integrins Cancer Res. 1996, 56, 1939-47
31. Walker-Nasir, E.; Codington, J. F.; Jahnke, M. R.; Fuller, T. C.; Jeanloz, R. W. Isolation and partial characterization of surface components of cell line MDA-MB-231 derived from a human metastatic breast carcinoma J. Natl. Cancer Inst. 1982, 69, 371-80
32. Horoszewicz, J. S.; Leong, S. S.; Kawinski, E.; Karr, J. P.; Rosenthal, H.; Chu, T. M.; Mirand, E. A.; Murphy, G. P. LNCaP model of human prostatic carcinoma Cancer Res. 1983, 43, 1809-18
33. Goswami, R. K.; Liu, Y.; Liu, C.; Lerner, R. A.; Sinha, S. C. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin Mol. Pharmaceutics 2013, 10, 538-43
34. Matsumura, T.; Wolff, K.; Petzelbauer, P. Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin J. Immunol. 1997, 158, 3408-16
35. May, C.; Sapra, P.; Gerber, H. P. Advances in bispecific biotherapeutics for the treatment of cancer Biochem. Pharmacol. 2012, 84, 1105-12
36. LoRusso, P. M.; Canetta, R.; Wagner, J. A.; Balogh, E. P.; Nass, S. J.; Boerner, S. A.; Hohneker, J. Accelerating cancer therapy development: The importance of combination strategies and collaboration. Summary of an Institute of Medicine Workshop Clin. Cancer Res. 2012, 18, 6101-9
37. Milstein, C.; Cuello, A. C. Hybrid hybridomas and their use in immunohistochemistry Nature 1983, 305, 537-40
38. Ellerman, D.; Scheer, J. M. Generation of bispecific antibodies by chemical conjugation. In Bispecific Antibodies; Kontermann, R. E., Ed.; Springer (www.springer.com): 2011; pp 47-63.